Technology area: Medical Devices & Mechanical Engineering
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Xinguang Bio-Pharmaceutical Ltd. has 1 pending office action within the Medical Devices & Mechanical Engineering technology area. This activity is concentrated under 1 distinct examiner and 1 distinct art unit, reflecting a highly focused prosecution strategy. This singular point of contact suggests that the company's current patent efforts are directed toward a specific mechanical or medical device technology rather than a broad suite of innovations.
The busiest examiner for this profile is LE, QUYNH DAO, who is currently managing the 1 busiest examiner pending office action. As the only examiner involved in the company's active filings, their specific review process and interpretation of the relevant statutes will determine the immediate outcome for the portfolio. The involvement of only 1 distinct examiner simplifies the prosecution process but also means the company's success is subject to the individual tendencies of this one official.
With 1 pending office action and 1 distinct art unit involved, the applicant can focus their resources on a single set of technical and procedural requirements. This streamlined profile is typical for companies with a very specific intellectual property goal. Practitioners should monitor the specific patterns of the Medical Devices & Mechanical Engineering unit to better understand the environment for this single pending matter and its potential for allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LE, QUYNH DAO | 1 | 33.3% | +12.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18020939 | FLUID TREATMENT METHOD AND FLUID TREATMENT DEVICE | LE, QUYNH DAO | — |
| Art Unit | Apps |
|---|---|
| 3781 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18020939 | FLUID TREATMENT METHOD AND FLUID TREATMENT DEVICE | LE, QUYNH DAO | 3781 | §103 | Non-Final OA | — | Pending | Mar 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Xinguang Bio-Pharmaceutical Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Quynh Dao Le has the most, with 1 of Shanghai Xinguang Bio-Pharmaceutical Ltd.'s pending office actions.
Mostly Medical Devices & Mechanical Engineering (USPTO Tech Center 3700), based on where its pending office actions are examined.
